ql1604
mAbexperimental
Clinical trial activity
7 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
3
Phase 4
0
Earliest trial started May 29, 2019 (NCT05649761)
Timeline
Indications
Mechanism of action
- Programmed cell death protein 1INHIBITOR
PDCD1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06789796 | Phase 3 | Feb 28, 2025 | Qilu Pharmaceutical Co., Ltd. |
| NCT05603039 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2021 | Qilu Pharmaceutical Co., Ltd. |
| NCT04864782 | Phase 2/Phase 3 (Phase 3) | Sep 23, 2020 | Qilu Pharmaceutical Co., Ltd., Sun Yat-Sen University |
| NCT05801094 | Phase 1 | Jul 20, 2020 | Fudan University, Qilu Pharmaceutical Co., Ltd. |
| NCT04435652 | Phase 2/Phase 3 (Phase 3) | Jul 1, 2020 | Qilu Pharmaceutical Co., Ltd. |
| NCT04326829 | Phase 2 | Apr 30, 2020 | Qilu Pharmaceutical Co., Ltd. |
| NCT05649761 | Phase 1 | May 29, 2019 | Qilu Pharmaceutical Co., Ltd. |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Qilu Pharmaceutical Co., Ltd. | For profit | 7 | 7 | 3 | 2019 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 0 | 1 | 2020 |
3 organizations
Page 1 / 1